B-Type Natriuretic Peptide as an Alternative Way of Assessing Total Cardiovascular Risk in Patients With Diabetes Mellitus

Dawson, Adelle; Jeyaseelan, S.; Morris, Andrew D.; Struthers, Allan D.

doi:10.1016/j.amjcard.2005.05.050

Cited by 19 publications

(15 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, in type 1 diabetes NT-proBNP is associated with micro-and macrovascular complications and is a predictor of cardiovascular mortality (73,74). Recent studies also have demonstrated that NT-proBNP predicts cardiovascular events in T2D patients and has a greater predictive value than other well-established cardiac risk markers (2,75,76). Collectively, these data suggest the possible use of NTproBNP as a tool for risk stratification, and preliminary data support this approach.…”

Section: Diabetes Complicationsmentioning

confidence: 59%

Natriuretic Peptides, Heart, and Adipose Tissue: New Findings and Future Developments for Diabetes Research

2014

View full text Add to dashboard Cite

Natriuretic peptides (NPs) play a key role in cardiovascular homeostasis, counteracting the deleterious effects of volume and pressure overload and activating antibrotic and antihypertrophic pathways in the heart. N-terminal B-type NP (NT-proBNP) also is a promising biomarker of global cardiovascular risk in the general population, and there is increasing interest on its potential use in diabetic patients for screening of silent cardiovascular abnormalities, cardiovascular risk stratification, and guided intervention. Recently, both atrial NP (ANP) and B-type NP (BNP) have emerged as key mediators in the control of metabolic processes including the heart in the network of organs that regulate energy usage and metabolism. Epidemiological studies have shown that ANP and BNP are reduced in people with obesity, insulin resistance, and diabetes, and this deficiency may contribute to enhance their global cardiovascular risk. Moreover, ANP and BNP have receptors in the adipose tissue, enhance lipolysis and energy expenditure, and modulate adipokine release and food intake. Therefore, low ANP and BNP levels may be not only a consequence but also a cause of obesity, and recent prospective studies have shown that low levels of NT-proBNP and midregional proANP (MR-proANP) are a strong predictor of type 2 diabetes onset. Whether ANP and BNP supplementation may result in either cardiovascular or metabolic benefits in humans remains, however, to be established.Natriuretic peptides (NPs) have gained great interest as indicators of the state of cardiovascular health across the spectrum of cardiovascular diseases (CVD) in diabetic subjects (1-4). Recently, NPs also have emerged as key mediators in the control of metabolic processes (5) and have been implicated in the development of diabetes (6,7), shifting current paradigms and opening novel avenues in diabetes research. This review will summarize new findings in the field and discuss their potential clinical relevance. NPS AND THEIR RECEPTORSNPs are a family of genetically distinct and structurally related peptides, including atrial NP (ANP), B-type NP (BNP), and C-type NP (CNP). They share a similar structural conformation, characterized by a peptide ring with a cysteine bridge, which is well preserved throughout evolution, being the portion of the chain that binds to the receptor. ANP and BNP are predominantly secreted by cardiomyocytes, whereas CNP is mainly produced by the central nervous system, the endothelium, the bone, and the reproductive system (8-11).

show abstract

Section: Diabetes Complicationsmentioning

confidence: 59%

Natriuretic Peptides, Heart, and Adipose Tissue: New Findings and Future Developments for Diabetes Research

2014

View full text Add to dashboard Cite

show abstract

“…2 Not surprisingly therefore, measurements of plasma BNP and NT-proBNP levels have been found to be useful in assessing prognosis in acute coronary syndromes (ACS) with and without diastolic dysfunction. [3][4][5][6][7][8][9][10][11][12] It is believed that such measurements could complement those of other prognostic biomarkers such as troponins and markers of the infl ammatory process, especially C-reactive protein (CRP).…”

Section: Methodsmentioning

confidence: 99%

Body Mass and Atherogenic Dyslipidemia as Major Determinants of Blood Levels of B-Type Natriuretic Peptides in Arab Subjects With Acute Coronary Syndromes

Akanji

Suresh

Al-Radwan³

et al. 2009

Metabolic Syndrome and Related Disorders

View full text Add to dashboard Cite

In an Arab population with CHD, blood levels of BNP are higher than in a healthy control population and appear correlated to body mass and atherogenic lipids but not CRP, troponin, or ejection fraction. BNP levels did not appear to be influenced by the classical CHD risk factors of diabetes, hypertension, cigarette smoking, hematocrit, or WHR. The independent link with atherogenic dyslipidemia suggests that BNP is important in atherogenesis and may not be just an index of cardiac contractile dysfunction.

show abstract

“…In subjects with diabetes, Dawson et al [97 ] suggest that BNP measurement may serve as a pragmatic alternative to multivariable cardiovascular risk estimation. The value of such prognostic tests in guiding primary prevention deserves study.…”

Section: Does Risk Scoring Influence An Individual's Risk Behaviours?mentioning

confidence: 99%

“…Glycosylated haemoglobin is included in the UK Prospective Diabetes Study (UKPDS) risk engine [19] and the Royal College of Physicians of Edinburgh method [20], whereas in the Cardiff score [45] duration of diabetes is used. Dawson et al [97 ] suggest that serum B-type natrurietic peptide (BNP) may improve risk estimation in patients with diabetes.…”

Section: Risk Scoring In Diabetesmentioning

confidence: 99%

Risk scoring in the assessment of cardiovascular risk

Beswick

Brindle

2006

Current Opinion in Lipidology

View full text Add to dashboard Cite

Numerous risk scoring methods are available to the healthcare professional but use is patchy. Accuracy varies between populations and methods have been developed to compensate for some of this variability. If risk scoring methods are to be widely used in general practice, evidence is required on both the accuracy of methods in appropriate populations and their effectiveness in improving health outcomes.

show abstract

B-Type Natriuretic Peptide as an Alternative Way of Assessing Total Cardiovascular Risk in Patients With Diabetes Mellitus

Cited by 19 publications

References 4 publications

Natriuretic Peptides, Heart, and Adipose Tissue: New Findings and Future Developments for Diabetes Research

Natriuretic Peptides, Heart, and Adipose Tissue: New Findings and Future Developments for Diabetes Research

Body Mass and Atherogenic Dyslipidemia as Major Determinants of Blood Levels of B-Type Natriuretic Peptides in Arab Subjects With Acute Coronary Syndromes

Risk scoring in the assessment of cardiovascular risk

Contact Info

Product

Resources

About